Cardiopulmonary effects of vasopressin versus norepinephrine in patients undergoing cardiac surgery: A single-center, cluster-randomized crossover trial

What Was Tested

This randomized controlled trial paper looks at Vasopressin.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Their single-center, cluster-randomized multiple crossover trial enrolled patients undergoing elective cardiac surgery who developed systemic hypotension (mean arterial pressure <70 mm Hg) and cardiac index >2.2 L/min/m2.

A predefined subanalysis examined the effect of norepinephrine versus vasopressin in patients with preoperative pulmonary hypertension.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

Randomization was performed in 1-week blocks (total of 46 weeks) where vasopressin or norepinephrine were assigned as the initial vasopressor.

Their primary outcome was the time-weighed average mean pulmonary artery pressure to systemic mean arterial pressure ratio and their secondary outcome was right ventricular free wall strain by transesophageal echocardiography, both measured between start and end of chest closure.

What Was Measured

Topics PubMed links to this paper include Vasopressins, Cardiac Surgical Procedures, Norepinephrine, Vasoconstrictor Agents, Ventricular Function, Right, Arterial Pressure and Hypertension, Pulmonary.

The authors tagged it with the keywords cardiac surgery, postcardiopulmonary bypass vasoplegia, pulmonary hypertension and vasopressors.

What This Means in Plain Language

The paper is a randomized and crossover study of Vasopressin.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (The Journal of thoracic and cardiovascular surgery), a journal based in United States.

More context: the Vasopressin compound page, all human trials.